Send2Press Newswire
Wed, 01 Sep 2010 21:00:19 GMT
Jury Provides Split Verdict in Leader v. Facebook Patent Infringement Trial
COLUMBUS, Ohio, July 29 (SEND2PRESS NEWSWIRE) -- Today Leader Technologies Incorporated announced the results of the Leader v. Facebook patent infringement trial, in which an eight-member jury in Wilmington, Delaware, returned a split verdict on Wednesday, July 28th.
The jury concluded that Facebook literally infringes all of the asserted claims of Leader's patent, and that the published prior art cited by Facebook did not anticipate or make obvious Leader's invention. Facebook had alleged numerous technologies that predated Leader's invention, but these were rejected by the decision.
The jury found for Facebook when they agreed with Facebook's claim that the patent was invalid due to commercial activity by Leader prior to the patent's issuance.
Company founder and CEO Mike McKibben said: "We are very pleased with the jury's findings that Facebook infringes our patent. We were disappointed with the invalidity finding, and will ask that it be set aside. We believe that Facebook presented no 'clear and convincing' evidence that would invalidate our patent."
Attorney Paul Andre from King & Spalding, the firm that represented Leader, said that if the invalidity finding regarding commercial activity is set aide, the jury's decision that Facebook infringes Leader's patent will stand.
Both Facebook and Leader will present briefs to the court beginning on Monday, and the case will remain in litigation for some time.
About Leader:
Leader Technologies Incorporated is located in Columbus, Ohio and offers other communications and alerting products and may be reached thru Jim Sobwick at 614-890-1986 or online at www.leader.com.
NEWS SOURCE: Leader Technologies Incorporated
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2010 Neotrope® News Network - all rights reserved.
TAGS: Leader Technologies Incorporated, Legal and Law, Send2Press.
Thu, 29 Jul 2010 18:39:42 GMT
Vitamin E Cosmetic Foam Patent Filed by Enefco
Patent Now Pending on a New Vitamin E Foam Manufacturing Process.
AUBURN, Maine, July 19 (SEND2PRESS NEWSWIRE) -- A U.S. patent has been filed by Enefco USA for a new process of applying Vitamin E as a surface coating on non-latex hydrophilic polyurethane cosmetic foam. The patent pending process adds Vitamin E to the foam after the foam is manufactured and impregnates the foam in a range from surface coating to complete saturation.
"Vitamin E hydrophilic polyurethane foam is in high demand in the cosmetic industry," says Peter Klein, President/CEO at Enefco USA, Inc. "Our customers have been requesting a more cost effective and consistent Vitamin E foam."
"We are very pleased with how our process successfully coats and penetrates our cosmetic foams with Vitamin E," said John Condon, Director of Operations for Enefco.
"We can vary the surface concentration of Vitamin E applied. Once the cosmetic foam is thoroughly coated it passes through our system of rollers designed to aid the penetration of Vitamin E. The new process does not change the consistent softness of our cosmetic foams, which still maintains its supple, velveteen feel and texture. The Vitamin E is available on any foam densities we manufacture."
About Enefco USA, Inc.:
Enefco, operating in Auburn, Maine for over 90 years, manufactures high-quality non-latex hydrophilic polyurethane cosmetic foam. Our experienced manufacturing abilities allow us to manufacture, cut, and package cosmetic foam within our 75,000 square foot manufacturing facility. ENcell cosmetic foam is available in a variety of thicknesses and densities, providing a range of quality products to meet our customer's demands and expectations.
For more information, please visit www.enefco-foam.com.
NEWS SOURCE: Enefco USA, Inc.
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2010 Neotrope® News Network - all rights reserved.
TAGS: Enefco USA, Inc., Patent and Trademark, Send2Press.
Mon, 19 Jul 2010 13:12:12 GMT
Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate with Additional U.S. Patents
Tumor-targeted Gene Delivery Gains in Medicine and Patent Protection.
SAN MARINO, Calif., July 6 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances covering tumor-targeted gene delivery and precision-targeted cancer immunotherapy, respectively. Like the exceedingly tiny, precision targeted, stealthy tumor-seeking nanomedicine itself, this small California biotechnology company has advanced to the forefront of the biopharmaceutical "War on Cancer" with formal demonstrations of safety and efficacy in the clinic and best-of-breed solutions for the pharmaceutical industry.
As the development of its lead oncology product advances in the clinic towards regulatory approval, the critical proofs-of-principle, i.e., definitive demonstrations of overall safety and single-agent efficacy in clinical trials, serve as the scientific and innovative basis for attaining additional patent protections in the emerging field of tumor-targeted biologics. Indeed, Epeius Biotechnologies has accumulated more than 150 issued/allowed/granted patents in the area of genetic medicine, including more than 40 pending applications.
Furthermore, the U.S. FDA has recently granted Orphan Drug status to Rexin-G, the company's lead product, for three separate clinical indications based on formal evaluations of clinical safety and potential efficacy, which provides additional market protections and economic incentives pertaining to such a significant and yet unmet medical need as the treatment of chemotherapy-resistant cancers.
Exhibiting broad-spectrum anti-cancer activity against many otherwise intractable cancers, Rexin-G has demonstrated a number of first-in-class, best-in-class characteristics: (1) The tumor-targeting properties of the gene delivery platform are profound, capable of seeking-out, accumulating-in, and halting-the-progression-of widespread cancers by means of simple intravenous infusions. (2) The broad-spectrum anti-cancer activity is achieved "by design," as the genetic payload is focused on a critical locus of cellular growth control and tumor suppression. (3) Years of progressive clinical trials have advanced the field by establishing cumulative safety (with no dose-limiting toxicities), practical pharmacological thresholds, quantitative dose-response relationships, and clinical infusion protocols which optimize patient benefits, including significant survival benefits. (4) Equally important are the advancements in biopharmaceutical science that provide for greater purities, potencies, GMP productivity, and economies-of-scale, and which translate into more-affordable treatments for cancer patients.
All in all, it seems that Small, Smart, and Stealth may turn out to be a very cool hand to grasp, and to hold on to.
About Epeius Biotechnologies:
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems. Rexin-G® is currently approved for the treatment of all chemotherapy-resistant solid tumors by the Philippine FDA. To learn more about our lead products and/or our pipeline of proprietary biotechnologies, please visit us at www.epeiusbiotech.com.
For recent papers, expert reviews, clinical reports in oncology and molecular therapy, etc., see the "Publications" section on our website.
NEWS SOURCE: Epeius Biotechnologies Corporation
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2010 Neotrope® News Network - all rights reserved.
TAGS: Epeius Biotechnologies Corporation, Drugs and Pharmaceuticals, Send2Press.
Tue, 06 Jul 2010 16:42:17 GMT
SecuGen Awarded Fingerprint Patents in Canada and Japan
SANTA CLARA, Calif., June 16 (SEND2PRESS NEWSWIRE) -- SecuGen, the world's leading optical fingerprint device vendor, is pleased to announce that it has been awarded patents in Canada and Japan. In Canada, SecuGen was awarded patents for the inventions entitled "Method and Apparatus for Reduction of Trapezoidal Distortion and Improvement of Image Sharpness in an Optical Image Capturing System" and "Optical Fingerprint Image Capturing System." In Japan, it was awarded a patent for "High Contrast, Low Distortion Optical Acquisition System for Image Capturing."
SecuGen currently holds a patent portfolio consisting of 35 patents, most of which are at the core of SecuGen's fingerprint recognition technology. SecuGen's sensors are well known for capturing very high quality, high contrast images and for being rugged. They are made of a hardened glass that is extremely resistant to scratching. These sensors are used in all of SecuGen's USB fingerprint readers as well as SecuGen's OEM fingerprint modules.
SecuGen sells its fingerprint readers and OEM fingerprint modules through a worldwide network of several hundred partners, ranging from systems integrators and software developers to hardware manufacturers. As a consequence of its worldwide sales channels SecuGen products are being used in over 80 countries.
Won Lee, CEO of SecuGen said, "For more than a decade we have worked to develop and manufacture a suite of fingerprint biometric products that are targeted to the real world commercial and government implementations that our partners are so focused on. While we are very proud of these new patent grants and believe that they are a result of our effectively focused efforts, we are not resting. SecuGen continues to work hard to both improve our existing products and invent tomorrow's products."
About SecuGen:
SecuGen Corporation (www.secugen.com) is the world's leading provider of advanced, optical fingerprint recognition technology, products, tools and platforms for physical and information security. SecuGen designs and develops FBI-certified fingerprint readers and OEM components, developer kits and software, including NIST/MINEX-compliant algorithms. Known for high quality, ruggedness, and performance in a wide variety of applications and environmental conditions, SecuGen products are used by world-leading financial, medical, government, educational and corporate institutions and are sold through a partner network of over 200 original equipment manufacturers, independent software vendors and system integrators around the world.
SecuGen® is a registered trademark of SecuGen Corp. in the United States and other countries.
NEWS SOURCE: SecuGen Corporation
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2010 Neotrope® News Network - all rights reserved.
TAGS: SecuGen Corporation, Biometrics and Bioware, Send2Press.
Wed, 16 Jun 2010 11:35:58 GMT
USPTO Awards Key Patent to ADF Solutions for Digital Forensics
BETHESDA, Md., June 9 (SEND2PRESS NEWSWIRE) -- ADF Solutions, Inc., the leading provider of forensic triage tools for computers and peripherals, is pleased to announce that it has been granted a patent by the U.S. Patent and Trademark Office pertaining to methods of searching forensic data. The patent has critical applications for forensic triage, cyber-security, cyber-intelligence, digital forensics, and e-discovery.
The patent covers the company's innovative SearchPak® technology, which enables an organization to capture its digital forensic investigative strategy and share it across organizations and with other individuals while not revealing the actual content. The SearchPak hides the complexity of the detailed forensic search definition and stores it in a secure container that can be deployed and used by non-forensically trained operators. This process allows analysts and forensic examiners to control precisely the job performed by the operators.
For law enforcement and intelligence agencies, the SearchPak technology allows the agencies to share digital intelligence for investigations while still maintaining secrecy. This has been a major breakthrough for key agencies, as the inability to share key intelligence was identified as a major issue leading to the 9/11 attacks.
"This patent rewards ADF's efforts to bring innovative technologies to the digital forensics and cyber-security fields," said Raphael Bousquet, CTO and co-founder of ADF Solutions. "We are working on many other technologies as innovative as our SearchPaks, such as CapturePaks™ and ActivitySensor™, to extend the applicability of our tools."
The company has several other patents pending.
About ADF Solutions:
ADF Solutions, Inc. is the global leader in forensic triage tools for rapid evidence recovery and intelligence extraction from computers and peripheral devices. The tools have a proven track record of reducing forensic backlogs, securing fast convictions, and identifying suspects who are a threat to national security. The tools are designed to be used by both technical and nontechnical users and are widely deployed for both field and lab investigations. ADF Solutions' clients include major law enforcement, defense, customs border, and intelligence agencies worldwide.
For more information, visit www.adfsolutions.com.
"SearchPak" is a registered trademark of ADF Solutions. "CapturePak" and "ActivitySensor" are trademarks of ADF Solutions. All other trademarks referenced herein are the property of their respective owners.
NEWS SOURCE: ADF Solutions, Inc.
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2010 Neotrope® News Network - all rights reserved.
TAGS: ADF Solutions, Inc., Software, Send2Press.
Wed, 09 Jun 2010 12:12:04 GMT
Titan Lenders Corp Announces Patent for Cerberyx Mortgage Fulfillment Services Platform
DENVER, Colo., May 12 (SEND2PRESS NEWSWIRE) -- Mortgage fulfillment outsource services expert, Titan Lenders Corp (TLC), a partner in Cerberyx LLC with eSys Technologies, LLC is pleased to announce the issuance of U.S. Patent 7,707,153 (other patent pending) related to the Cerberyx (CBX) web-based automated workflow platform. The CBX platform supports and makes possible a full suite of fulfillment services, including: closing, funding, post-closing, quality control, purchase review for correspondents and purchasing investors, asset review for warehouse lenders, trailing documents, MERs management, FHA insuring, and document management (imaging).
"To say that we are pleased that this patent has been granted is an understatement," said TLC president Mary Kladde. "This patent affirms our decision to focus on building out a comprehensive mortgage fulfillment platform that serves the industry's need for precision loan level quality production coupled with 100% visibility that encourages 100% accountability."
Co-developed with eSys Technologies in the practical laboratory of a high volume closing and post-closing environment, CBX executes operational efficiencies both through accountability and transparency. CBX flexible rules-based architecture allows TLC clients to define field level decision trees, priorities, checklists and process management specific to an investor product variance or a cross-investor and cross-warehouse line climate. The platform links the people, processes and data in a mortgage transaction and fills the gap between origination and post closing.
"When combined with Titan's unrivaled expertise and perfectionism, Cerberyx dramatically compresses the time and money it takes to process a mortgage through closing and sale," Kladde explained. "Best practice execution and its superior automation enable TLC to truncate post-closing processes, which in turn accelerates investor transactions and shortens warehouse line turn times."
Cerberyx is the evolution of a software technology application developed to replace manual processes required to manage the lender's participation in closing and post-closing functions. As a business solution, the software was developed in a closing and post-closing division servicing multiple lenders, investors, warehouse lines, and lending business channels. It addresses the needs of all users in the transaction, providing accountability, visibility, efficiency and ease of use while never losing sight of the end goal: loan salability. Flexible to client requirements, Cerberyx dramatically cuts FTE requirements while enhancing quality loan production.
About Titan Lenders Corp:
Titan Lenders Corp (www.titanlenderscorp.com) is one of a specialized few providers of mortgage back office fulfillment services, a not-well-understood facet of mortgage lending that includes closing, funding, and post closing services. Community banks, credit unions, mortgage bankers and brokers use outsource providers strategically to minimize compliance risks in a time-sensitive error-averse environment. Fluctuations in mortgage lending volume also lead some lenders outsource their entire back office operation and secure predictable "per transaction" pricing rather than maintaining an inflexible static in house staff.
About eSys Technologies, LLC:
eSys Technologies (www.esystechnologies.com) is a Rochester, NY-based business to business solution provider focused on facilitating and optimizing the entire residential mortgage closing process in both traditional paper-based and evolving electronic-based forms, and the secure transfer of data between specified parties. Development efforts based on over 30 years experience in residential mortgage lending and legal software solution programming began in December, 1997 to meet the needs for a process management and document production system capable of handling the most complex mortgage lending processing. The eSys(R) family of Centerware products encompasses computer software for process management and tracking, closing services coordination, administrative auto-reporting, process status auto-notification, issues management and tracking, regulatory compliance enforcement, electronic document archiving, data collection, data exchange, document production, and life of transaction history.
NEWS SOURCE: Titan Lenders Corp
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2010 Neotrope® News Network - all rights reserved.
TAGS: Titan Lenders Corp, Patent and Trademark, Send2Press.
Wed, 12 May 2010 07:59:15 GMT
Authernative Granted US and Japanese Patents for User Authentication
REDWOOD CITY, Calif., March 17 (SEND2PRESS NEWSWIRE) -- Authernative, Inc., a leading developer of innovative user authentication and identity management technologies, announced today that it recently has been granted three patents, two from the United States Patent Office and one from the Japanese Patent Office for its user authentication methods.
The newly issued patent number US 7,681,228 titled "Method of one time authentication response to a session-specific challenge indicating a random subset of a password or PIN character positions" and patent numbers US 7,644,433 and JP 4421892 titled "Authentication System and Method Based upon Random Partial Pattern Recognition" describe "what user knows" authentication methods which provide stronger security than traditional passwords.
The three patents add to Authernative's intellectual property portfolio for authentication methods based on the Random Partial Shared Secret Recognition algorithm, which include different types of knowledge-based shared secrets, such as standard passwords and PINs, enhanced passwords, and pattern-based one-time PINs.
In contrast with the standard static password recognition algorithm which requires the user to enter the entire password in one authentication session, the patented Random Partial Shared Secret Recognition algorithm requests only a random subset of the user's credentials each authentication session. As such, the user never discloses or gives away the entire PIN, password, or pattern-based shared secret during any login session. This technology significantly reduces the credential's entropy leakage and renders one-time authentication responses difficult to compromise. Moreover, the method's virtual keyboards, menus, and grids containing digital content such as letters, numbers, images or colors, enable high combinatorial capacity and an easy cognitive way to select, remember, and enter the user's credentials. The combination of these security and usability features provide stronger protection against known attacks including phishing, key logging, brute force, Trojan horse and other spyware attacks.
The patented technology is one of a number of authentication methods available in Authernative's AuthGuard® product. The AuthGuard® versatile authentication server offers a range of legacy and innovative authentication methods having scalable security, high usability, electronic deployment, low total cost of ownership, and self-service capabilities. AuthGuard® authentication options include enhanced password, pattern-based one-time PIN, one-time challenge one-time response, out-of-wallet questions, out-of-band, OTP, mobile soft client and mutual authentication. These authentication factors, used alone or in combination, allow for one-factor, layered, and multi-factor authentication security. All are provided through a single product suite implemented in a multi-tenant architecture, enabling secure access of different authentication groups. This allows the personalization of the level of security and the ease-of-use particular to users' needs or companies' policies aimed at complying with Government, Financial, and Healthcare security standards.
AuthGuard® securely authenticates users over distributed network environments for Web, VPN, Citrix, online collaboration and mobile access to mass consumer providers, enterprises, e-commerce, cloud computing, SaaS, or On-Demand services. The authentication methods can be used from any access device such as computers, mobile devices, smart cards, VoIP terminals, personal media players, Point-of-Sale, ATM, set-top box, or touch screen displays, providing a common user experience.
AuthGuard® includes patented front-end authentication algorithms, and on the back-end, it utilizes the patented encryption key management system combined with the mutual authentication protocol. The CrosSecure® Authernative® Cryptographic Module has been FIPS 140-2 certified by the National Institute of Standards and Technology (USA).
Authernative's granted patents add to the company's patent portfolio solidifying the company's ability to provide innovative, secure and cost-effective user authentication solutions. With identity theft, cyber crime, phishing, and data breaches escalating to an all time high, enterprises, government agencies, online service providers, and consumers can benefit from AuthGuard® authentication product to secure access to networks, extranets, portals, applications, data and mobile devices.
About Authernative:
Authernative is a leading provider of innovative software security solutions offering identity and access management capabilities including authentication, authorization, administration, and auditing. The company's products are used to prevent unauthorized online access to confidential data, protected resources, and financial transactions. They allow organizations to lower the cost of providing, deploying, and managing user authentication for enabling e-commerce, e-government, and regulatory compliance.
More information: www.authernative.com.
NEWS SOURCE: Authernative, Inc.
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2010 Neotrope® News Network - all rights reserved.
TAGS: Authernative, Inc., Patent and Trademark, Send2Press.
Wed, 17 Mar 2010 12:28:20 GMT
Epeius Biotechnologies Receives Notice of Patent Allowance for Tumor-Targeted Cancer Vaccines
Precision-targeted Reximmune-C® recruits cancer patient's inner SWAT team.
SAN MARINO, Calif., March 16 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for a crucial patent covering its leading tumor-targeted vaccine technology for cancer immunotherapy. The issuance of this valuable patent protection for tumor targeted immunotherapy follows on the heels of two international patents covering targeted gene medicine in the U.S. and Europe, respectively, and places Epeius Biotech at the forefront of these emerging fields of clinical medicine with best-of-breed solutions and incontrovertible proofs-of-principle in the clinic.
The advent of pathotropic (disease-seeking) targeting technology first enabled the development of tumor-targeted Rexin-G, which seeks-out, accumulates-in, and selectively delivers a lethal designer gene to tumors that have spread throughout the body (metastatic cancer), halting the progression of disease while improving both survival and quality-of-life. Approved for all solid tumors in the Philippines, Rexin-G has received Orphan Drug and Fast Track status from the U.S. FDA, and is currently moving on to Phase III trials for first-line and second-line indications.
Once the control of tumor growth has been achieved with Rexin-G®, the need to extend the treatment intervals and/or clinical remissions led to the development of Reximmune-C, a second tumor-targeted genetic medicine which delivers a pulse of immune-stimulating cytokine directly to the sites of residual or recurrent disease, thereby recruiting the patient's own immune system into the lesions of the residual cancer to invoke a more lasting anti-tumor immune response.
Much like a SWAT (special weapons and tactics) Team that calls an elite police force to the scene of a crime, Reximmune-C acts at the local level, recruiting the body's own professional immune cells, antigen-presenting cells, helper cells, and killer T-cells directly to the locus of the residual cancer, where tumor debris as antigens are abundant.
This provides the patient with an opportunity to mount a beneficial immune response that would further improve clinical outcome. Unlike, previous approaches to personalized cancer vaccination, a simple intravenous infusion of tumor-targeted Reximmune-C marshals the cadre of complex immunological responses of this intrinsic SWAT Team to the place where it is needed most. By reaching beyond the boundaries of medicine to the very crux of metastatic disease, Epeius delivers another vital innovation.
About Epeius Biotechnologies:
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems.
To learn more about our pipeline of proprietary biotechnologies, please visit us at www.epeiusbiotech.com.
NEWS SOURCE: Epeius Biotechnologies Corporation
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2010 Neotrope® News Network - all rights reserved.
TAGS: Epeius Biotechnologies Corporation, Drugs and Pharmaceuticals, Send2Press.
Tue, 16 Mar 2010 06:58:47 GMT
Patented CAVTEC Technology Quantifies Competitive Advantage and Value
SYRACUSE, N.Y., Nov. 5 (SEND2PRESS NEWSWIRE) -- CAVTEC (www.cavtectools.com) announces the formal launch of CAV, Competitive Advantage Valuation software for maximizing returns on intellectual property (IP). Field tested in over 100 projects since 1997, CAV has helped universities, businesses, and entrepreneurs develop effective IP strategies and negotiate successful agreements. As a result, in 2009 Technology Transfer Tactics (TTT) chose the CAV solution for its specialized valuation catalog (www.technologytransfertactics.com) and showcased CAV at the recent Licensing Executives Society (LES) annual meeting. TTT is a highly respected publication of best practices for research, commercialization and licensing professionals.
Ted Hagelin, CAVTEC CEO, notes: "We have seen tremendous growth in the value of IP. Today, about 83 percent of S&P 500 companies' market value is attributable to intangible property. As market value grew, so did the volume of IP exchanges and the importance of accurately and objectively valuing these assets in the absence of public trading markets and standardized exchange terms. Until now IP valuation methods have been either inexpensive but yielding very coarse results, or simply out of reach financially for most users. CAV was developed to strike a unique balance between cost and precision."
David Schwartz, TTT CEO and Publisher adds, "Technology Transfer Tactics is proud to partner with CAVTEC, because CAV fills a real need for our subscribers - a low-cost, comprehensive valuation tool that calculates an equal rate of return for licensors and licensees."
Mary Maida PhD, CEO of Medingen (www.medingen.com), a CAV customer, concurs, stating: "Our clients are in every stage of technology development, from feasibility through launch. We find CAV to be extremely useful and flexible."
About CAV:
CAV is a repeatable, comprehensive approach to IP valuation. It features a step-by-step method for quantifying factors that determine a technology's competitive advantage in a given market.
Packaged as PC-based software, key CAV applications include:
• valuing early-state technologies
• negotiating patent licenses
• determining venture investments
• predicting IP success in the marketplace
• performing due diligence
• calculating infringement damages.
CAV, patented by CAVTEC founder Ted Hagelin, is based on his extensive expertise. Hagelin is nationally recognized for IP valuation through his work as the Director of Syracuse University's Technology Commercialization Research Center and his research on intellectual property strategy and patent valuation. He teaches intellectual property and technology commercialization law at Syracuse University College of Law.
More information: www.cavtectools.com.
NEWS SOURCE: CAVTEC
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2009 Neotrope® News Network - all rights reserved.
TAGS: CAVTEC, Software, Send2Press.
Thu, 05 Nov 2009 18:52:31 GMT
Authernative Granted U.S. Patent on Key Generation Method for Encryption and Authentication System
REDWOOD CITY, Calif., Oct. 26 (SEND2PRESS NEWSWIRE) -- Authernative, Inc., the leading developer of innovative user authentication and identity management technologies, announced today that the United States Patent and Trademark Office has granted the company its patent for encryption key generation method. The newly issued U.S. Patent No. 7,577,987 titled "Key generation method for communication session encryption and authentication system" describes a new encryption key management system integrated with a two-factor authentication protocol.
This system provides for mutual authentication of the connected parties in a client-server architecture which results in a secure distribution of secret session-only random symmetric encryption keys that are generated at the server and distributed to clients.
The wide proliferation of B2B and B2C e-commerce networks enabling connections from user's mobile devices, laptop/desktop computers, ATMs, POS terminals, set-top boxes, VOIP phones, GPS and other data processing devices necessitates enhancement of the security infrastructure at the consumer level, especially in the area of user authentication and data-in-transit security. Usage of Public Key Infrastructure (PKI) has certain limitations at the mass user level due to technology deployment complexities, cost, and administration of the consumers' keys / certificates. Authernative-patented MEDIA™ protocol overcomes these PKI issues by using two-factor authentication credentials adopted in e-commerce with the benefit of providing seamless mutual authentication and a secure session-only random symmetric encryption key distribution enabling further secure data exchange.
"Authernative's encryption key management system enables an easy to administer high security solution," said Dr. Len Mizrah, President and CEO of Authernative. "The advantage of the MEDIA™ protocol is a capability to mutually authenticate with the server either a client platform or a human user at the client platform, depending on credentials utilized. In both cases, it protects from pharming or phishing attacks respectively."
The security of the key exchange in the MEDIA™ protocol is based on innovative algorithms enabling the following three Authernative-patented technologies: (1) a key generation architecture utilizing the Time Interplay Limited SRK (Session Random Key) Algorithm (TILSA™) - U.S. Patent No. 7,577,987, (2) a key exchange protocol utilizing the TILSA™ algorithm and communication parties' authentication credentials with Key Encryption/Decryption Iterative Algorithm (KEDIA™) - U.S. Patent No. 7,506,161, and (3) a Key Conversion Array (KCA™) technology providing for high security message exchange over non-trusted communication media by utilizing either of patented algorithms: Bit-Veil-Unveil (BitVU™), Byte-Veil-Unveil (ByteVU™), and Bit-Byte-Veil-Unveil (BBVU™) - U.S. Patent No. 7,299,356.
These patented technologies embedded into Authernative AuthGuard® user authentication product enable strong user authentication and client-server mutual authentication during the authentication stage of the communication session and secure exchanges of encryption keys to allow secure content delivery. The CrosSecure® Authernative® Cryptographic Module integrated into AuthGuard® has received FIPS 140-2 certification from the National Institute of Standards and Technology (USA).
AuthGuard® offers a suite of one-factor, layered, and multi-factor authentication to meet a variety of security and usability requirements. AuthGuard® user authentication is electronically mass deployable, has scalable security, high usability, low total cost of ownership, and efficient integration/customization options with legacy environments. The product provides fully automated operation modes for secure login, set-up, and reset of all AuthGuard® authentication methods including enhanced password, pattern-based one-time password, one-time challenge one-time response, out-of-band, one-time pin, and secure in-band authentication.
The newly granted patent solidifies the company's ability to provide innovative, secure and cost-effective user authentication solutions. With identity theft, cyber crime, and data breaches escalating to an all time high, enterprises, government agencies, online service providers, and consumers can benefit from the AuthGuard® authentication product to secure access to networks, extranets, portals, applications, data and devices.
About Authernative, Inc.:
Authernative is a leading provider of innovative software security solutions offering identity and access management capabilities including authentication, authorization, administration, and auditing. The company's products are used to prevent unauthorized online access to confidential data, protected resources, and financial transactions. They allow organizations to lower the cost of providing, deploying and managing user authentication for enabling e-commerce, e-government, and regulatory compliance.
More information: www.authernative.com.
NEWS SOURCE: Authernative, Inc.
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2009 Neotrope® News Network - all rights reserved.
TAGS: Authernative, Inc., Safety and Security Solutions, Send2Press.
Mon, 26 Oct 2009 12:30:28 GMT
|
